TY - JOUR T1 - Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam JF - medRxiv DO - 10.1101/2022.02.01.22270253 SP - 2022.02.01.22270253 AU - Anh Duc Dang AU - Thiem Dinh Vu AU - Ha Hai Vu AU - Van Thanh Ta AU - Anh Thi Van Pham AU - Mai Thi Ngoc Dang AU - Be Van Le AU - Thai Huu Duong AU - Duoc Van Nguyen AU - Saranath Lawpoolsri AU - Pailinrut Chinwangso AU - Jason S. McLellan AU - Ching-Lin Hsieh AU - Adolfo Garcia-Sastre AU - Peter Palese AU - Weina Sun AU - Jose L. Martinez AU - Irene Gonzalez-Dominguez AU - Stefan Slamanig AU - Juan Manuel Carreño AU - Johnstone Tcheou AU - Florian Krammer AU - Ariel Raskin AU - Huong Minh Vu AU - Thang Cong Tran AU - Huong Mai Nguyen AU - Laina D. Mercer AU - Rama Raghunandan AU - Manjari Lal AU - Jessica A. White AU - Richard Hjorth AU - Bruce L. Innis AU - Rami Scharf Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/02/05/2022.02.01.22270253.abstract N2 - Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S is an inactivated egg-based Newcastle disease virus (NDV) vaccine expressing the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Wuhan-Hu-1. The spike protein was stabilized and incorporated into NDV virions by removing the polybasic furin cleavage site, introducing the transmembrane domain and cytoplasmic tail of the fusion protein of NDV, and introducing six prolines for stabilization in the prefusion state. Vaccine production and clinical development was initiated in Vietnam, Thailand, and Brazil. Here the interim results from the first stage of the randomized, dose-escalation, observer-blind, placebo-controlled, phase 1/2 trial conducted at the Hanoi Medical University (Vietnam) are presented. Healthy adults aged 18-59 years, non-pregnant, and with self-reported negative history for SARS-CoV-2 infection were eligible. Participants were randomized to receive one of five treatments by intramuscular injection twice, 28 days apart: 1 μg +/-CpG1018 (a toll-like receptor 9 agonist), 3 μg alone, 10 μg alone, or placebo. Participants and personnel assessing outcomes were masked to treatment. The primary outcomes were solicited adverse events (AEs) during 7 days and subject-reported AEs during 28 days after each vaccination. Investigators further reviewed subject-reported AEs. Secondary outcomes were immunogenicity measures (anti-spike immunoglobulin G [IgG] and pseudotyped virus neutralization). This interim analysis assessed safety 56 days after first vaccination (day 57) in treatment-exposed individuals and immunogenicity through 14 days after second vaccination (day 43) per protocol. Between March 15 and April 23, 2021, 224 individuals were screened and 120 were enrolled (25 per group for active vaccination and 20 for placebo). All subjects received two doses. The most common solicited AEs among those receiving active vaccine or placebo were all predominantly mild and included injection site pain or tenderness (<58%), fatigue or malaise (<22%), headache (<21%), and myalgia (<14%). No higher proportion of the solicited AEs were observed for any group of active vaccine. The proportion reporting vaccine-related AEs during the 28 days after either vaccination ranged from 4% to 8% among vaccine groups and was 5% in controls. No vaccine-related serious adverse event occurred. The immune response in the 10 μg formulation group was highest, followed by 1 μg +CpG1018, 3 μg, and 1 μg formulations. Fourteen days after the second vaccination, the geometric mean concentrations (GMC) of 50% neutralizing antibody against the homologous Wuhan-Hu-1 pseudovirus ranged from 56.07 IU/mL (1 μg, 95% CI 37.01, 84.94) to 246.19 IU/mL (10 μg, 95% CI 151.97, 398.82), with 84% to 96% of vaccine groups attaining a ≥ 4-fold increase over baseline. This was compared to a panel of human convalescent sera (N=29, 72.93 95% CI 33.00-161.14). Live virus neutralization to the B.1.617.2 (Delta) variant of concern was reduced but in line with observations for vaccines currently in use. Since the adjuvant has shown modest benefit, GMC ratio of 2.56 (95% CI, 1.4 - 4.6) for 1 μg +/-CpG1018, a decision was made not to continue studying it with this vaccine. NDV-HXP-S had an acceptable safety profile and potent immunogenicity. The 3 μg dose was advanced to phase 2 along with a 6 μg dose. The 10 μg dose was not selected for evaluation in phase 2 due to potential impact on manufacturing capacity. ClinicalTrials.gov NCT04830800.Competing Interest StatementBVL, THD and DVN are salaried employees of the Institute of Vaccines and Medical Biologicals (IVAC, Vietnam). RH is a paid consultant to PATH. WS reports royalty payments from Avimex. AGS reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051). The AGS laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines and Merck. AGS. has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories and Pfizer, PP reports financial support from the U.S. NIAID (Centers of Excellence for Influenza Research and Response 75N93021C00014, P01 AI097092-07, R01 AI145870-03). FK reports financial support from the U.S. NIAID (Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051,  Center of Excellence for Influenza Research and Surveillance contract HHSN272201400008C), the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611, 5384), and the U.S. NCI ( contract 75N91019D00024, task order 75N91020F00003); he also has received royalties (Avimex), consulting fees (Pfizer, Seqirus, and Avimex), and payment for academic lectures during the past two years.  CLH and JSM report financial support from the Bill & Melinda Gates Foundation and the U.S. NIH. The vaccine administered in this study was developed by faculty members at the Icahn School of Medicine at Mount Sinai including WS, PP, AGS, and FK. Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and the NDV-based SARS-CoV-2 vaccine; the institution and its faculty inventors could benefit financially. JSM and CLH are inventors on a patent application concerning the Hexapro stabilized SARS-CoV-2 spike protein that was filed by the University of Texas at Austin and has been licensed to multiple entities; the university and its faculty inventors could benefit financially.Clinical TrialNCT04830800Funding StatementActivities at PATH and Mount Sinai were supported, in part, by the Bill & Melinda Gates Foundation (INV-021239). PATH was also supported by the Coalition for Epidemic Preparedness (CEPI) and Bayer AG. Under the grant conditions of the Bill & Melinda Gates Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. The findings and conclusions contained within this manuscript are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation. The salary of PP was partially funded by NIH (Centers of Excellence for influenza Research and Response, 75N93021C00014), U.S. NIAID grant (P01 AI097092-07), U.S. NIAID grant (R01 AI145870-03), by the NIH Collaborative Influenza Vaccine Innovation Centers contract 75N93019C00051 and a grant from an anonymous philanthropist to Mount Sinai. Design and generation of reagents used in this project in the Kramer laboratory were supported by Centers of Excellence for influenza Research and Response (75N93021C00014) and Collaborative Influenza Vaccine Innovation Centers (75N93019C00051), as was the Garcia-Sastre laboratory. Research and development activities in Vietnam were funded by IVAC, the National Covid-19 Vaccine Fund and the Thien Tam Fund of Vingroup. Testing of clinical trial specimens at Nexelis was supported by CEPI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was jointly approved by the Institutional Review Board of the Vietnam National Institute of Hygiene and Epidemiology as well as the Independent Ethics Committee of the Vietnam Ministry of Health (Approval Ref: 24/CN-HDDD dated 23 February, 2021) and authorized by the Vietnam Ministry of Health (Authorization reference: 1407/QD-BYT dated 26 February, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study protocol is provided in the appendix. Individual participant data will be made available when the trial is complete, upon request directed to Assoc. Prof. Thiem Dinh Vu (vdt{at}nihe.org.vn). After approval of a proposal, data can be shared through a secure online platform. ER -